Everything below concerns mitochondrial biogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
1993/1332) Functions of Traffic Wardens (Amendment) Order 1993 (S.I. 1993/1334) Food Protection (Emergency Prohibitions) (Paralytic Shellfish Poisoning) Order 1993 (S.I. 1993/1338) Local Government (Committees) (Amendment) Regulations 1993 (S.I. 1993/1339) Merchant Shipping (Fees) (Amendment) Regulations 1993 (S.I. 1993/1340) Finance (No. 2) Act 1992 (Commencement No. 5) Order 1993 (S.I. 1993/1341) Heathrow Airport (County and London Borough Boundaries) Order 1993 (S.I. 1993/1342) Lambeth, Merton and Wandsworth (London Borough Boundaries) Order 1993 (S.I. 1993/1343) Fishing Vessels (Decommissioning) Scheme 1993 (S.I. 1993/1345) Ealing, Hammersmith and Fulham, and Hounslow (London Borough Boundaries) Order 1993 (S.I. 1993/1346) Tayside Regional Council (Backwater and Lintrathen Reservoirs) Byelaws Extension Order 1993 (S.I. 1993/1347) Unfair Dismissal (Increase of Compensation Limit) Order 1993 (S.I. 1993/1348) North and Central London (London Borough Boundaries) Order 1993 (S.I. 1993/1351) North London Boroughs (London Borough Boundaries) Order 1993 (S.I. 1993/1352) Customs and Excise (Transit) Regulations 1993 (S.I. 1993/1353) Civil Legal Aid (Scope) Regulations 1993 (S.I. 1993/1354) Act of Sederunt (Fees of Shorthand Writers in the Sheriff Court) 1993 (S.I. 1993/1355) Act of Sederunt (Rules of the Court of Session Amendment No.3) (Shorthand Writers' Fees) 1993 (S.I. 1993/1357) Haringey and Islington (London Borough Boundaries) Order 1993 (S.I. 1993/1358) Farmed Game Meat (Hygiene and Inspection) (Charges) Regulations 1993 (S.I.
== Risk factors == Hospitals are primary transmission sites for CRE-based infections. Up to 75% of hospital admissions attributed to CRE were from long-term care facilities or transferred from another hospital. Suboptimal maintenance practices are the largest cause of CRE transmission. This includes the failure to adequately clean and disinfect medication cabinets, other surfaces in patient rooms, and portable medical equipment, such as X-ray and ultrasound machines that are used for both CRE and non-CRE patients. Thus far, CRE have primarily been nosocomial infectious agents. Almost all CRE infections occur in people receiving significant medical care in hospitals, long-term acute care facilities, or nursing homes. Independent risk factors for CRE infection include use of beta-lactam antibiotics and the use of mechanical ventilation. Patients with diabetes have also been shown to be at an elevated risk for acquiring CRE infections. When compared to other hospitalized patients, those admitted from long-term acute care (LTAC) facilities have significantly higher incidence of colonization and infection rates. Another 2012 multicenter study found that over 30% of patients with recent exposure to LTAC were colonized or infected with CRE. A person susceptible to CRE transmission is more likely to be female, have a greater number of parenteral nutrition-days (days when the person received nutrition via the bloodstream), and to have had a significant number of days breathing through a ventilator.
== Function == Dermcidin is a secreted protein that is subsequently processed into mature peptides of distinct biological activities. The C-terminal peptide is constitutively expressed in sweat and has antibacterial and antifungal activities. The N-terminal peptide, also known as diffusible survival evasion peptide, promotes neural cell survival under conditions of severe oxidative stress. A glycosylated form of the N-terminal peptide may be associated with cachexia (muscle wasting) in cancer patients.
Sources: en.wikipedia.org
== Background == Mays was born in Reynoldsville, West Virginia, in 1975. She was a United States Army West Virginia National Guard veteran who served from November 2000 to April 2001 and again from February 2003 to May 2004, when she deployed to Iraq and Kuwait with the 1092nd Engineer Battalion. Prior to beginning her employment as a nursing assistant at the Louis A. Johnson Veterans Medical Center, Mays had worked as a corrections officer at the West Virginia Department of Corrections at North Central Regional Jail in Greenwood, West Virginia, between 2005 and 2012. In 2013, Mays was one of several defendants in a lawsuit that was brought by an inmate incarcerated at the jail who alleged that he had been repeatedly beaten by Mays and other correction officers. The lawsuit was dismissed on summary judgment. Mays was a longtime member of Monroe Chapel United Methodist, a small church approximately twenty minutes outside Clarksburg in Lost Creek.
The first studies measuring drugs in biological fluids were carried out to determine possible overdosing as part of the new science of forensic medicine/toxicology. Initially, nonspecific assays were applied to measuring drugs in biological fluids. These were unable to discriminate between the drug and its metabolites; for example, aspirin (c. 1900) and sulfonamides (developed in the 1930s) were quantified by the use of colorimetric assays. Antibiotics were quantified by their ability to inhibit bacterial growth. The 1930s also saw the rise of pharmacokinetics, and as such the desire for more specific assays. Modern drugs are more potent, which has required more sensitive bioanalytical assays to accurately and reliably determine these drugs at lower concentrations. This has driven improvements in technology and analytical methods. Some techniques commonly used in bioanalytical studies include:
The adjacent figure shows a typical fission product distribution from the fission of uranium. Note that in the calculations used to make this graph, the activation of fission products was ignored and the fission was assumed to occur in a single moment rather than a length of time. In this bar chart results are shown for different cooling times (time after fission). Because of the stability of nuclei with even numbers of protons and/or neutrons, the curve of yield against element is not a smooth curve but tends to alternate. Note that the curve against mass number is smooth.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.